Ambulatory infusion aids in management of chronic disease conditions such as cancer, cancer related pain, hemophilia, immune deficiencies, Crohn’s disease, congestive heart failure, rheumatoid arthritis, multiple sclerosis, dehydration, malnutrition, and chronic inflammatory diseases. Ambulatory infusions may be provided by variety of organizations such as hospitals, community pharmacies, and home health agencies. Ambulatory infusion is administration of various types of medications and fluids intravenously into the bloodstream by the help of needle or catheter.
The global ambulatory infusion center market is estimated to be valued at US$ 47,013.5 million in 2020 and is expected to exhibit a CAGR of 9.0% during the forecast period (2020-2027).
Figure 1. Global Ambulatory Infusion Center Market Value (US$ Mn), 2016-2027
The increasing prevalence of cancer is expected to propel growth of the global ambulatory infusion center market during the forecast period. For instance, according to the Our World in Data, an organization focusing on research and data of world’s largest health problems, stated that, in 2017, globally 9.6 million people were estimated to have died from the various types of cancer and also stated that, in 2017, every sixth death caused in the world was due to cancer.
Furthermore, key companies focusing on service launches such as ambulatory infusion centers for chemotherapy is expected to propel growth of the global ambulatory infusion center market during the forecast period. For instance, in June 2020, Cedar-Sinai launched Samuel Oschin Cancer Center in Los Angeles, a center with 45,000-square-foot outpatient facility, providing ambulatory infusion services for cancer patients.
Ambulatory Infusion Center Market Report Coverage
||Market Size in 2020:
||US$ 47,013.5 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 51,244.7 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of the Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Therapy Type: Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy, Others.
- By Application: Chronic Inflammatory Disorders, Neurological Disorders, Cancers, Nutrition Support, Gastro-intestinal Disorders.
- By Distribution Channel: Hospital, Clinics, Home Infusion.
Option Care Health, PharmaScript, Cleveland Clinic, Stoughton Health, Coram CVS, Hattiesburg Clinic, UnitedHealth Group, UK HealthCare, CHI Health, PharMerica, Beacon Health System, Inc., Arnot Health, Inc. , IVX Health and Precision Healthcare
- Increasing prevalence of various diseases such as cancer, multiple sclerosis, and gastrointestinal diseases, globally
- Key players focusing on inorganic growth strategies such as mergers and acquisitions
|Restraints & Challenges:
- Ambulatory infusion leads to various side effects such as itching at infusion site, flushing, nausea, and cough in patients.
Global Ambulatory Infusion Center Market – Impact of Coronavirus (COVID-19)
Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in over 65.1 million infected individuals worldwide as of December 3, 2020.
COVID-19 pandemic has affected the ambulatory infusion center market negatively, owing to increasing risk of coronavirus infection spread, while carrying out infusion procedures. Therefore various academic institutes and research institutes are guiding safety procedures during the administration of various medication through infusion procedures to avoid the COVID-19 infections. According to American College of Rheumatology report published in April 2020, stated that healthcare professionals can carry out following safety precaution guidelines to decrease the risk of spreading COVID-19 infections during ambulatory infusion procedures:
- Clean and decontaminate facilities frequently using a disinfectant known to be effective, and ensure the appropriate contact time for the disinfectant
- All equipment and high-touch surfaces in patient care areas should be cleaned and disinfected between each patient use, along with special attention to other high-touch surfaces in check-in areas and around the facility
- Inform patients of social distancing and hygiene procedures
- Adjust waiting rooms to allow for social distancing, placing chairs six feet or more apart, and consider asking patients to wait for their appointment outside the facility
- Hand sanitizer should be readily available in patient care areas
Figure 2. Global Ambulatory Infusion Center Market Share (%), By Region, 2020
North America is expected to hold dominant position in the global ambulatory infusion center market during the forecast period, owing to key companies focusing on expanding service facilities of ambulatory infusion for the treatment of various diseases such as cancer and others. For instance, in May 2018, Keck Medicine of University of Southern California's medical enterprise (USC), announced expansion of its network of ambulatory clinics with a new location in Southern California. The new facility offers a wide range of primary care and specialty services such as ambulatory infusion services for people suffering from various disorders such as cancer, gastrointestinal disorders.
Major players operating in the global ambulatory infusion center market include Option Care Health, PharmaScript, Cleveland Clinic, Stoughton Health, Coram CVS, Hattiesburg Clinic, UnitedHealth Group, UK HealthCare, CHI Health, PharMerica, Beacon Health System, Inc., Arnot Health, Inc., IVX Health, and Precision Healthcare.